Study of Safety and Immunogenicity of BVRS-GamVac

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of \~34.5%. The aim of the study is to assess the safety and immunogenicity of adenoviral-based vaccine against MERS - BVRS-GamVac.
Epistemonikos ID: 89a45197c06e3e3bdf7224d15ae0a89e20cf1315
First added on: Mar 23, 2020